Trump nominates Chris Klomp as HHS second-in-command

Trump Nominates Chris Klomp as HHS Second-in-Command

Trump nominates Chris Klomp as HHS second – President Donald Trump has selected Chris Klomp, currently serving as Medicare’s chief administrator, to assume the role of deputy secretary at the U.S. Department of Health and Human Services (HHS). This appointment positions Klomp as the second-ranking official under Secretary Robert F. Kennedy Jr., a role he has been actively supporting for months. The decision marks a strategic reshuffling within the administration, aimed at streamlining leadership and reinforcing key policy initiatives.

Key Responsibilities of the Deputy Secretary Role

The deputy secretary’s duties encompass overseeing the operational efficiency of HHS and steering regulatory policy. This position is critical in ensuring the agency’s agenda aligns with presidential priorities. Klomp’s nomination follows a period of leadership changes, as the department has been without a deputy since Jim O’Neill’s departure in February. O’Neill’s exit was part of a broader restructuring effort to refocus health care messaging on cost reduction and the promotion of the TrumpRx program.

Background on Chris Klomp’s Career

Chris Klomp, a former health care executive, has been in his current role as Medicare director since April 2025. His tenure has been marked by efforts to negotiate deals with pharmaceutical companies under the TrumpRx initiative, a program designed to lower prescription drug costs for American consumers. Klomp’s involvement in these negotiations has positioned him as a key figure in the administration’s health care strategy, particularly in shaping the most-favored nations plan.

“The Health and Human Services department is a vast and intricate entity, yet Chris Klomp possesses the expertise to manage it effectively,” President Trump remarked in a recent post on Truth Social. He emphasized that the decision to appoint Klomp was a collaborative effort, stating, “You don’t know his name as much as some of the others, but he’s a real star of the group.”

During a White House event in April, Trump highlighted Klomp’s contributions to a landmark agreement with Regeneron, a major pharmaceutical company. The president praised the move, describing it as a pivotal moment in advancing the administration’s health care reforms. Klomp’s leadership in this context has earned him recognition as a reliable and capable figure within the HHS framework.

Leadership Vacancy and Replacements

Since the departure of Jim O’Neill, HHS has faced a leadership gap, with Klomp stepping in to coordinate internal operations and guide regulatory efforts. His selection as deputy secretary underscores his familiarity with the department’s structure and his ability to navigate its complexities. The Senate must now confirm his appointment, joining a list of other federal health nominees awaiting hearings before the Senate Health, Education, Labor and Pensions Committee.

Following the resignation of Dr. Marty Makary, who led the U.S. Food and Drug Administration (FDA) until May, Klomp has also played a central role in identifying a replacement. His involvement in these high-level searches reflects his growing influence within the administration’s health policy apparatus. Additionally, Klomp oversaw the recruitment of candidates for the U.S. Centers for Disease Control and Prevention (CDC) and the surgeon general’s office this year, a task that required balancing political considerations with public health expertise.

Senate Confirmation Process

Klomp’s nomination will now undergo scrutiny by the Senate, where confirmation hearings are standard for top federal appointments. The process typically involves detailed questioning about his qualifications, policy positions, and past decisions. His selection adds another layer to the administration’s health care agenda, as the Senate prepares to evaluate his readiness to lead HHS in a new era of policy focus.

Meanwhile, the White House has continued its efforts to promote the TrumpRx program, which aims to reduce drug prices through market-driven reforms. Klomp’s role in these negotiations has been instrumental, particularly in ensuring alignment between HHS and pharmaceutical companies. His ability to bridge administrative and industry interests has been a key asset in advancing the program’s objectives.

Broader Implications for HHS Leadership

The appointment of Klomp signals a shift toward consolidating control within the HHS leadership. By placing a trusted advisor in a high-ranking position, Trump has reinforced the agency’s alignment with his administration’s health care priorities. This move also highlights the importance of internal expertise in managing a sprawling department that oversees numerous critical functions, from public health initiatives to regulatory oversight.

With the Senate confirmation process ahead, Klomp’s tenure as deputy secretary is expected to focus on both maintaining existing policies and implementing new strategies. His prior work in Medicare administration and regulatory affairs positions him well to address the agency’s evolving challenges. As HHS continues to navigate the complexities of health care reform, Klomp’s leadership will be a central factor in shaping the department’s direction.

Context of the Appointment

The timing of Klomp’s nomination coincides with ongoing efforts to redefine HHS’s role in the health care landscape. His experience in managing Medicare operations and negotiating with industry stakeholders has been a driving force behind the Trump administration’s push for cost-cutting measures. The deputy secretary position, now filled by Klomp, will be crucial in executing these plans while ensuring the agency’s operations remain stable and effective.

Trump’s decision to appoint Klomp also reflects a broader strategy of relying on insiders who have already demonstrated success within the administration. His close collaboration with Secretary Robert F. Kennedy Jr. has been a hallmark of his career, and this new role is likely to further solidify their working relationship. As the health care landscape continues to evolve, Klomp’s appointment ensures continuity in key initiatives and strategic vision.

Throughout his tenure, Klomp has balanced the demands of regulatory oversight with the need for pragmatic solutions. His work on the most-favored nations plan, which seeks to lower prescription drug costs by incentivizing price negotiations, has been a centerpiece of the administration’s health care reforms. This initiative, now underklomp’s leadership, is expected to continue gaining traction as the Senate and other stakeholders evaluate its potential impact.

Future Outlook for HHS

As HHS moves forward with its new leadership structure, the department’s ability to implement policy changes will depend on the effectiveness of its deputy secretary. Klomp’s appointment brings a wealth of experience and a clear understanding of the agency’s operations, making him a strong candidate for the role. His confirmation is anticipated to be a critical step in finalizing the administration’s health care strategy and addressing ongoing challenges in the sector.

With the confirmation process underway, attention will turn to how Klomp’s leadership will influence HHS’s priorities in the coming months. The department’s focus on cost reduction, regulatory efficiency, and public health initiatives is expected to remain central, as he works alongside Secretary Kennedy Jr. to ensure these goals are met. This appointment not only fills a leadership void but also reinforces the administration’s commitment to its health care agenda.